2015 Fiscal Year Final Research Report
Development of a novel targeting therapy using anti-podoplanin antibody against malignant pleural mesothelioma
Project/Area Number |
25460189
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Medical pharmacy
|
Research Institution | The University of Tokushima |
Principal Investigator |
ABE Shinji 徳島大学, 大学院医歯薬学研究部, 助教 (00403717)
|
Co-Investigator(Kenkyū-buntansha) |
NISHIOKA Yasuhiko 徳島大学, 大学院医歯薬学研究部, 教授 (70274199)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Keywords | トランスレーショナルリサーチ / 抗体医薬 / ADCC / ポドプラニン / 個別医療 / 悪性胸膜中皮腫 |
Outline of Final Research Achievements |
Malignant pleural mesothelioma (MPM) is mainly caused by exposure to asbestos, develops in the pleural cavity with a high likelihood of malignancy. Development of novel therapies for MPM is warranted in order to improve very poor prognosis. In this study, we investigated whether anti-human podoplanin antibodies can induce antitumor effects in MPM. Using podoplanin positive human MPM cell lines, anti-human podoplanin antibodies with NK cells induced significant antitumor effect. Our results strongly suggest that anti-human podoplanin antibodies might provide an efficacious therapeutic strategy for the treatment of MPM.
|
Free Research Field |
臨床薬学
|